Literature DB >> 22561144

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Mark D Gershman1, J Erin Staples, Adwoa D Bentsi-Enchill, J Gabrielle Breugelmans, Glacus S Brito, Luiz Antonio Bastos Camacho, Pascale Cottin, Cristina Domingo, Anna Durbin, Joaquim Gascon, Fouzia Guenaneche, Edward B Hayes, Zsuzsanna Jelenik, Alena Khromava, Reinaldo de Menezes Martins, Mario Masana Wilson, Nathalie Massy, Abdulsalami Nasidi, Matthias Niedrig, Adam Sherwat, Theodore Tsai, Anna Vilella, Mary Elizabeth Wilson, Katrin S Kohl.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22561144      PMCID： PMC3425393          DOI： 10.1016/j.vaccine.2012.04.067

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  53 in total

Review 1.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses.

Authors:  D Moher; D J Cook; S Eastwood; I Olkin; D Rennie; D F Stroup
Journal:  Lancet       Date:  1999-11-27       Impact factor: 79.321

2.  Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology.

Authors:  G D Grossfeld; M S Litwin; J S Wolf; H Hricak; C L Shuler; D C Agerter; P R Carroll
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

3.  Effects of yellow fever vaccination.

Authors:  V Adhiyaman; A Oke; C Cefai; V Adhiyaman; A Oke; C Cefai
Journal:  Lancet       Date:  2001-12-01       Impact factor: 79.321

4.  Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency.

Authors:  F Ghaffar; K Carrick; B B Rogers; L R Margraf; K Krisher; O Ramilo
Journal:  Pediatr Infect Dis J       Date:  2000-08       Impact factor: 2.129

5.  Hepatitis and death following vaccination with 17D-204 yellow fever vaccine.

Authors:  R C Chan; D J Penney; D Little; I W Carter; J A Roberts; W D Rawlinson
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

6.  Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases.

Authors:  P F Vasconcelos; E J Luna; R Galler; L J Silva; T L Coimbra; V L Barros; T P Monath; S G Rodigues; C Laval; Z G Costa; M F Vilela; C L Santos; P M Papaiordanou; V A Alves; L D Andrade; H K Sato; E S Rosa; G B Froguas; E Lacava; L M Almeida; A C Cruz; I M Rocco; R T Santos; O F Oliva; C M Papaiordanou
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

7.  Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

Authors:  M Martin; T F Tsai; B Cropp; G J Chang; D A Holmes; J Tseng; W Shieh; S R Zaki; I Al-Sanouri; A F Cutrona; G Ray; L H Weld; M S Cetron
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

Review 8.  Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

Authors:  D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

Review 9.  Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.

Authors:  Bruno Guy; Farshad Guirakhoo; Veronique Barban; Stephen Higgs; Thomas P Monath; Jean Lang
Journal:  Vaccine       Date:  2009-10-04       Impact factor: 3.641

10.  Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study.

Authors:  Anna H Roukens; Darius Soonawala; Simone A Joosten; Adriëtte W de Visser; Xiaohong Jiang; Kees Dirksen; Marjolein de Gruijter; Jaap T van Dissel; Peter J Bredenbeek; Leo G Visser
Journal:  PLoS One       Date:  2011-12-07       Impact factor: 3.240
View more
  14 in total

1.  Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data.

Authors:  Stephen J Seligman; Joel E Cohen; Yuval Itan; Jean-Laurent Casanova; John C Pezzullo
Journal:  Am J Trop Med Hyg       Date:  2014-01-06       Impact factor: 2.345

2.  Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories.

Authors:  Cristina Domingo; Pranav Patel; Jasmin Yillah; Manfred Weidmann; Jairo A Méndez; Emmanuel Rivalyn Nakouné; Matthias Niedrig
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

Review 3.  Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

Authors:  Thomas P Monath; Stephen J Seligman; James S Robertson; Bruno Guy; Edward B Hayes; Richard C Condit; Jean Louis Excler; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2014-10-27       Impact factor: 3.641

Review 4.  Current status and future prospects of yellow fever vaccines.

Authors:  Andrew S Beck; Alan D T Barrett
Journal:  Expert Rev Vaccines       Date:  2015-09-14       Impact factor: 5.217

5.  Notes from the field: fatal yellow fever vaccine-associated viscerotropic disease--Oregon, September 2014.

Authors:  Malini DeSilva; Arun Sharma; Erin Staples; Byron Arndt; Wun-Ju Shieh; Jim Shames; Paul Cieslak
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-03-20       Impact factor: 17.586

6.  Serious adverse events associated with yellow fever vaccine.

Authors:  Reinaldo de Menezes Martins; Maria da Luz Fernandes Leal; Akira Homma
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.

Authors:  Sophia Gailhardou; Anna Skipetrova; Gustavo H Dayan; John Jezorwski; Melanie Saville; Diane Van der Vliet; T Anh Wartel
Journal:  PLoS Negl Trop Dis       Date:  2016-07-14

Review 8.  Yellow fever vaccine-associated viscerotropic disease: current perspectives.

Authors:  Roger E Thomas
Journal:  Drug Des Devel Ther       Date:  2016-10-12       Impact factor: 4.162

9.  Notes from the Field: Investigation of Patients Testing Positive for Yellow Fever Viral RNA After Vaccination During a Mass Yellow Fever Vaccination Campaign - Angola, 2016.

Authors:  Andrew T Boyd; Diambi Dombaxe; Rosa Moreira; M S Oliveira; Eusebio Manuel; Carlos Navarro Colorado; Tatiana M Lanzieri
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-03-17       Impact factor: 17.586

10.  17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study.

Authors:  Reinaldo M Martins; Maria de Lourdes S Maia; Roberto Henrique G Farias; Luiz Antonio B Camacho; Marcos S Freire; Ricardo Galler; Anna Maya Yoshida Yamamura; Luiz Fernando C Almeida; Sheila Maria B Lima; Rita Maria R Nogueira; Gloria Regina S Sá; Darcy A Hokama; Ricardo de Carvalho; Ricardo Aguiar V Freire; Edson Pereira Filho; Maria da Luz Fernandes Leal; Akira Homma
Journal:  Hum Vaccin Immunother       Date:  2013-01-30       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.